Metabolic syndrome: risk factors and molecular drug targets
EXCLI Journal · 29.08.2025 · 24 · 1193-1223
DOI: 10.17179/excli2025-8703 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 29.08.2025. Verfasst von Rishabh Chalotra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuroendocrinology and Metabolic Disorders, Department of Pharmacology, Central University of Punjab, Bathinda, India. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic syndrome (MetS), is a non-communicable disorder caused by impaired management and storage of energy, primarily associated with unhealthy diets, sedentary lifestyles and stress. It is diagnosed when any three of the following conditions are observed, obesity (primary factor), hyperglycemia, low HDL, hypertriglyceridemia, and hypertension (ATP III guidelines). MetS affects approximately 14-34 % of the global population, highlighting significant public health concern. If left untreated, it leads to the development of other serious metabolic diseases like atherosclerosis, diabetes, PCOS, NAFLD, NASH, thyroid, cancer, sleep disturbance, osteoarthritis, anxiety, and depression. Despite ongoing research, no first-line drug currently exists for the comprehensive management of MetS. Its multifactorial nature often requires lifelong polytherapy with lifestyle intervention, raising concern over chronic drug use, drug-drug interactions, increasing morbidity and mortality. Therefore, there is a need highlighting the requirement of a single and targeted pharmacotherapy which offers a safer and more specific therapeutic approach. This review aims to identify and analyse ten key molecular targets in managing the pathogenesis of Metabolic Syndrome (MetS). These targets can further pave the way for a targeted and safer approach in the treatment of MetS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Neuroendocrinology and Metabolic Disorders, Department of Pharmacology, Central University of Punjab, Bathinda, India.
- Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
Zitieren
APA
Chalotra, R., Gupta, A., Singh, T. G., & Singh, R. (2025). Metabolic syndrome: risk factors and molecular drug targets. EXCLI Journal, 24, 1193-1223. https://doi.org/10.17179/excli2025-8703
Vancouver
Chalotra R, Gupta A, Singh TG, Singh R. Metabolic syndrome: risk factors and molecular drug targets. EXCLI Journal. 2025;24:1193-1223. doi:10.17179/excli2025-8703
BibTeX
@article{Chalotra2025,
author = {Chalotra, Rishabh and Gupta, Aniket and Singh, Thakur Gurjeet and Singh, Randhir},
title = {Metabolic syndrome: risk factors and molecular drug targets},
journal = {EXCLI Journal},
year = {2025},
volume = {24},
pages = {1193--1223},
doi = {10.17179/excli2025-8703}
}
EUVIMED